| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000016702 |
| Receipt No. | R000013429 |
| Official scientific title of the study | Photodynamic diagnosis by using 5-aminolevulinic acid in pancreaticobiliary neoplasm |
| Date of disclosure of the study information | 2015/03/05 |
| Last modified on | 2016/04/10 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Photodynamic diagnosis by using 5-aminolevulinic acid in pancreaticobiliary neoplasm | |
| Title of the study (Brief title) | Diagnosis using 5-aminolevulinic acid in pancreaticobiliary neoplasm | |
| Region |
|
|
| Condition | ||
| Condition | Pancreaticobiliary tumor | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | To evaluate the diagnostic ability of 5-aminolevulinic acid in pancreaticobiliary neoplasm |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Diagnostic accuracy of 5-aminolevulinic acid in pancreaticobiliary neoplasm |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | A single oral administration of 5-aminolevulinic acid (1g) | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients who have an abnormality of biliary tree and/or pancreas.
2. Patients who provide a written informed consent. |
|||
| Key exclusion criteria | 1. Patients with porphyria.
2. Patients with hypersensitivity to 5-aminolevulinic acid or porphyrins. 3. In cases of known or suspected pregnancy or woman who are breast-feeding. 4. Patients who doctors regard as inappropriate ones for the enrollment due to some reasons. |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Tsukasa Ikeura |
| Organization | Kansai Medical University |
| Division name | The Third Department of Internal Medicine |
| Address | 2-5-1, Shinmachi, Hirakata, Osaka, Japan |
| TEL | 072-804-0101 |
| ikeurat@hirakata.kmu.ac.jp | |
| Public contact | |
| Name of contact person | Tsukasa Ikeura |
| Organization | Kansai Medical University |
| Division name | The Third Department of Internal Medicine |
| Address | 2-5-1, Shimachi, Hirakata |
| TEL | 072-804-0101 |
| Homepage URL | |
| ikeurat@hirakata.kmu.ac.jp | |
| Sponsor | |
| Institute | Kansai Medical University |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/icdr_e/ctr_view.cgi?recptno=R000013429 |